Article, see p 874 P atients with atrial fibrillation who are at an increased risk for stroke, but who are not good long-term candidates for oral anticoagulation, may derive benefit from left atrial appendage (LAA) occlusion. Among these benefits is a decreased risk of life-threatening bleeding.
Because of the limitations of the study design, no information was available regarding the specific echocardiographic characteristics of the DRT. Whether the DRT was flat, immobile, and layered, versus soft, mobile, and heterogeneous, would help in our understanding of the time frame for the observed DRT, and potentially of its risk for embolization (Figure) . We also do not know how patients were treated and anticoagulated following the diagnosis of DRT, which would be helpful in understanding if these events were preventable with immediate recognition. Similar to asymptomatic cerebral emboli following left atrial procedures, neurological imaging with brain magnetic resonance imaging and formal cognitive testing of subjects with DRT who were labeled as having no stroke or embolic event may help clarify the impact of DRT in these patients.
Individual factors associated with DRT included the presence of permanent atrial fibrillation, increasing CHA 2 DS 2 -VASc score, larger LAA diameter, lower LAA emptying flow velocity, and the presence of heart failure. It is likely that these factors are markers of a more fibrotic, immobile atrium with a low flow state and spontaneous echocardiogram contrast in the left atrium, which was not reported. The rate of DRT was consistent with prior large European registry data with a cumulative DRT incidence of 2.6% at 3 months, 3.7% at 12 months, and 4.1% after 2 years. [4] [5] [6] It is notable that patients in the European EWOLUTION registry (Registry on Watchman Outcomes in RealLife Utilization) were more likely to be sent home on dual antiplatelet therapy only or aspirin monotherapy after implant (67%). Because the majority of DRT is detected beyond 45 days, a single transesophageal echocardiogram at 45 days may not be optimal, and it may be that the recommended transesophageal echocardiography surveillance should be performed following the cessation of oral anticoagulation at 4 or 6 months postimplantation. Although this seems sensible based on the available data, it is a hypothesis that should be tested.
Thrombus formation on patent foramen ovale closure devices in patients with cryptogenic stroke appears to be less common than DRT on LAA occlusion devices. Patent foramen ovale occluders are implanted in much younger and healthier patients who usually do not have vascular disease, or atrial fibrillation, and are only treated with antiplatelet therapy after implant. 7 Perhaps atrial fibrillation itself is a prothrombotic state as supported by the association of permanent atrial fibrillation with DRT in Dukkipati et al. 3 Procedural factors are also likely to play a role in the development of DRT. Deep implantation of LAA occlusion devices with exposed/uncovered trabeculae, exposed metal at the attachment screw, and excessive compression of the device causing deformation of the surface of the device may all increase the likelihood of thrombus formation after anticoagulation is stopped, and warrant further study. The question remains, is there a better postprocedure medical regimen that might reduce the risk of DRT? Some clinicians favor extended postimplant oral anticoagulation beyond 45 days to 3 or 6 months to prevent thrombus formation during the endothelization process. In addition, it may be that low-dose direct oral anticoagulant therapy is superior to dual antiplatelet therapy between 45 days and 6 months after LAA occlusion. Again, these strategies need to be compared and tested. The inability to noninvasively detect an endothelial layer of tissue over the fabric cap and attachment screw is a limitation to more tailored and individualized therapy (Figure) . Resuming anticoagulation after DRT is detected should help reduce embolic events, but could also increase hemorrhagic events, especially in patients who are not good candidates for oral anticoagulation. It is curious that, despite the high-risk nature of these patients, the vast majority (>96%) of patients after LAA closure have no detected DRT on routine transesophageal echocardiography surveillance.
The time course of how long to treat a DRT and when, or if to eventually stop oral anticoagulation again if it resolves, is unknown. The authors should be commended for revising their impression, because they have previously published that DRT was not particularly associated with stroke or embolic events. 8 DRT is a challenging problem, a Catch-22 with no easy escape, in particular, because it occurs in the context of a procedure that is designed to avoid longterm anticoagulation. Keeping LAA occluders free of thrombus is a critically important goal, especially given the 1 in 4 risk of stroke when they are present. While we continue to investigate how to optimize monitoring and medical therapy after LAA occlusion, future LAA occlusion devices should be designed with these concerns in mind. 
